In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Athenex Inc. (NASDAQ:ATNX) reported that Prestine Victory Ltd. has picked up 3,181,817 of common stock as of 2017-07-05.
The acquisition brings the aggregate amount owned by Prestine Victory Ltd. to a total of 3,181,817 representing a 5.55% stake in the company.
For those not familiar with the company, Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company’s Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
A glance at Athenex Inc. (NASDAQ:ATNX)’s key stats reveals a current market capitalization of $1.02 Billion based on $55.25 Million shares outstanding and a price at last close of $17.79 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-06-19, Lau picked up 25,200 at a purchase price of $11.00. This brings their total holding to 2,747,922 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an Athenex Inc. (NASDAQ:ATNX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.